Resources from the same session
O-16: HEPANOVA: Final efficacy and safety results from a phase 2 study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC)
Presenter: Anca-Ligia Grosu, Germany
Session: Session V: Hepatocellular Cancer
Resources:
Webcast
O-1: Results from a global Phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma
Presenter: Ghassan Abou-Alfa, United States
Session: Session V: Hepatocellular Cancer
Resources:
Webcast
Discussant: LBA-2, O-1
Presenter: Chris Verslype, Belgium
Session: Session V: Hepatocellular Cancer
Resources:
Slides
Webcast
Q&A
Presenter: Michel Ducreux, France
Session: Session V: Hepatocellular Cancer
Resources:
Webcast
Pathogenesis and Pathology of HCC
Presenter: Jessica Zucman-Rossi, France
Session: Session V: Hepatocellular Cancer
Resources:
Slides
Webcast
How to Integrate and Sequence New Agents in HCC
Presenter: Ghassan Abou-Alfa, United States
Session: Session V: Hepatocellular Cancer
Resources:
Slides
Webcast
Challenges & indications for Locoregional treatment in HCC
Presenter: Maria Reig, Spain
Session: Session V: Hepatocellular Cancer
Resources:
Slides
Webcast
Q&A
Presenter: Michel Ducreux, France; Ghassan Abou-Alfa, United States; Maria Reig, Spain; Sharlene Gill, Canada
Session: Session V: Hepatocellular Cancer
Resources:
Webcast